Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company focused on chronic low back pain, published a shareholder letter from CEO Brent Ness on March 19, 2026, outlining the company's strategic progress and key catalysts for 2026. The letter emphasizes disciplined execution to expand adoption of its Nociscan platform, advance reimbursement initiatives, and strengthen clinical evidence.
Among the primary catalysts highlighted is the pursuit of reimbursement coverage from one or more regional insurance providers in the United States. According to the company, securing regional reimbursement is an important step toward broader payer adoption, which could significantly expand patient access to Nociscan. The platform uses magnetic resonance spectroscopy (MRS) and proprietary augmented intelligence algorithms to help physicians noninvasively identify painful discs in the lumbar spine.
Another key milestone is the initial readout from the CLARITY clinical trial, expected in the fourth quarter of 2026. The trial is designed to generate additional clinical evidence supporting Nociscan's efficacy, which could further strengthen the company's value proposition to physicians, payers, and patients. The full CEO Shareholder Letter is available on the company's website.
The letter also highlights Aclarion's strong balance sheet, with cash runway extending into 2028. This financial position provides the company with the resources to execute its strategic initiatives without near-term funding concerns. Ness stated, "With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain."
Since its commercial launch, Aclarion has focused on expanding physician and imaging center engagement. The Nociscan platform receives MRS data from an MRI machine via a cloud connection, extracts chemical biomarkers associated with disc pain, and uses algorithms to indicate whether a disc may be a pain source. This technology offers critical insights to optimize treatment strategies for chronic low back pain, a condition affecting millions.
The company's progress in the United Kingdom also features in the update, with ongoing reimbursement initiatives that could open additional markets. As Aclarion continues to build its clinical and reimbursement infrastructure, the 2026 catalysts represent pivotal steps toward broader commercial adoption. For more information on Nociscan and to find a nearby center, visit the company's site map.
With a focus on near-term milestones and a solid financial foundation, Aclarion aims to create long-term value for patients and shareholders while addressing the significant unmet need in chronic low back pain diagnosis and treatment. The latest news and updates relating to $ACON are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
